GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo

Blood

Volumn 127, Issue 16, 2016, Pages 2018-2027

  Pabst, Caroline ^a,b   Bergeron, Anne ^c   Lavallée, Vincent Philippe ^a,d   Yeh, Jonathan ^a   Gendron, Patrick ^a   Norddahl, Gudmundur L ^e   Krosl, Jana ^a   Boivin, Isabel ^a   Deneault, Eric ^a   Simard, Jessica ^c   Imren, Suzan ^e   Boucher, Geneviève ^a   Eppert, Kolja ^f   Herold, Tobias ^g   Bohlander, Stefan K ^h   Humphries, Keith ^e   Lemieux, Sébastien ^a,i   Hébert, Josée ^d,i   Sauvageau, Guy ^a,d,i   Barabé, Frédéric ^c,j,k  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c LAVAL UNIVERSITY   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF AUCKLAND   (New Zealand)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

^j LAVAL UNIVERSITY   (Canada)

^k UNIVERSITÉ LAVAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 56; UNCLASSIFIED DRUG; GPR56 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; ACUTE MYELOID LEUKEMIA CELL LINE; ADULT; ANIMAL EXPERIMENT; ARTICLE; CANCER STEM CELL; CELL POPULATION; ENGRAFTMENT; GENETIC RISK; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA STEM CELL; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; CELL CULTURE; CELL PROLIFERATION; CELL SEPARATION; HEK293 CELL LINE; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SURVIVAL ANALYSIS; TRANSGENIC MOUSE;

ADULT; ANIMALS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELLS, CULTURED; HEK293 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; RECEPTORS, G-PROTEIN-COUPLED; SURVIVAL ANALYSIS;

EID: 84973319291     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-11-683649     Document Type: Article

References (37)

1. Notta F, Doulatov S, Laurenti E, Poeppl A, Jurisica I, Dick JE. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science. 2011;333(6039):218-221.
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737.
3. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645-648.
4. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086-1093.
5. Taussig DC, Vargaftig J, Miraki-Moud F, et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood. 2010;115(10):1976-1984.
6. Sarry J-E, Murphy K, Perry R, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest. 2011;121(1):384-395.
7. Pabst C, Krosl J, Fares I, et al. Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat Methods. 2014;11(4):436-442.
8. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777-1784.
9. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167-1174.
10. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-299.
11. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005;82(5):389-396.
12. Iwasaki M, Liedtke M, Gentles AJ, Cleary ML. CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia. Cell Stem Cell. 2015;17(4):412-421.
13. Woiterski J, Ebinger M, Witte KE, et al. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome. Int J Cancer. 2013;133(7):1547-1556.
14. Pearce DJ, Taussig D, Zibara K, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006;107(3):1166-1173.
15. Imren S, Heuser M, Gasparetto M, et al. Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. Blood. 2014;124(24):3608-3612.
16. Miller PH, Cheung AMS, Beer PA, et al. Enhanced normal short-term human myelopoiesis in mice engineered to express human-specific myeloid growth factors. Blood. 2013;121(5):e1-e4.
17. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
18. Verhaak RGW, Wouters BJ, Erpelinck CAJ, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica. 2009;94(1):131-134.
19. Hebestreit K, Gröttrup S, Emden D, et al. Leukemia gene atlas-a public platform for integrative exploration of genome-wide molecular data. PLoS One. 2012;7(6):e39148.
20. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1-2):70-78.
21. Challen GA, Sun D, Mayle A, et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell. 2014;15(3):350-364.
22. Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell. 2010;7(4):532-544.
23. Hope KJ, Cellot S, Ting SB, et al. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell. 2010;7(1):101-113.
24. van Rhenen A, van Dongen GA, Kelder A, et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110(7):2659-2666.
25. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4(149):149ra118-149ra118.
26. Jan M, Chao MP, Cha AC, et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA. 2011;108(12):5009-5014.
27. Hosen N, Park CY, Tatsumi N, et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA. 2007;104(26):11008-11013.
28. Saito Y, Kaneda K, Suekane A, et al. Maintenance of the hematopoietic stem cell pool in bone marrow niches by EVI1-regulated GPR56. Leukemia. 2013;27(8):1637-1649.
29. Lavallée V-P, Gendron P, Lemieux S, D'Angelo G, Hébert J, Sauvageau G. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 2015;125(1):140-143.
30. Röllig C, Bornhäuser M, Thiede C, et al. Longterm prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29(20):2758-2765.
31. Hoadley KA, Yau C, Wolf DM, et al; Cancer Genome Atlas Research Network. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929-944.
32. Li Z, Herold T, He C, et al. Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol. 2013;31(9):1172-1181.
33. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014;28(8):1596-1605.
34. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41-47.
35. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012;120(15):2963-2972.
36. Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19(1):138-152.
37. Solaimani Kartalaei P, Yamada-Inagawa T, Vink CS, et al. Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation. J Exp Med. 2015;212(1):93-106.